J Korean Endocr Soc.  2010 Mar;25(1):18-21. 10.3803/jkes.2010.25.1.18.

Recent Developments of Anti-diabetic Agents Undergoing 2 and 3 Phase Clinical Trials

• Kim JG

• KMID: 2177855
• DOI: http://doi.org/10.3803/jkes.2010.25.1.18

Abstract

No abstract available.

Figure

• 

  Fig. 1 Glucose transporters in the renal proximal tubule in normal individuals.

Reference

1. Asano T, Ogihara T, Katagiri H, Sakoda H, Ono H, Fujishiro M, Anai M, Kurihara H, Uchijima Y. Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs. Curr Med Chem. 2004. 11:2717–2724.

2. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res. 2007. 56:91–98.

3. Buse JB. Glitazones and heart failure: critical appraisal for the clinician. Circulation. 2003. 108:E57.

4. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009. 11:81–89.

5. Hamren B, Bjork E, Sunzel M, Karlsson M. Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther. 2008. 84:228–235.

6. Hughes TE. Emerging therapies for metabolic diseases--the focus is on diabetes and obesity. Curr Opin Chem Biol. 2009. 13:332–337.

7. Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl. 2007. S27–S35.

8. Nomura S. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent. Curr Top Med Chem. 2010. [Epub ahead of print].

9. Paton CM, Ntambi JM. Biochemical and physiological function of stearoyl-CoA desaturase. Am J Physiol Endocrinol Metab. 2009. 297:E28–E37.

10. Pavankuamr VV, Vinu CA, Mullangi R, Srinivas NR. Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator. Eur J Drug Metab Pharmacokinet. 2007. 32:29–37.

11. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005. 4:14.

12. Waites CR, Dominick MA, Sanderson TP, Schilling BE. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist. Toxicol Sci. 2007. 100:248–258.

13. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007. 261:32–43.

14. Zhao G, Souers AJ, Voorbach M, Falls HD, Droz B, Brodjian S, Lau YY, Iyengar RR, Gao J, Judd AS, Wagaw SH, Ravn MM, Engstrom KM, Lynch JK, Mulhern MM, Freeman J, Dayton BD, Wang X, Grihalde N, Fry D, Beno DW, Marsh KC, Su Z, Diaz GJ, Collins CA, Sham H, Reilly RM, Brune ME, Kym PR. Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem. 2008. 51:380–383.